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REVIEW
Abstract: COPD is a widespread inﬂ  ammatory respiratory disorder characterized by a 
progressive, poorly reversible airﬂ  ow limitation. Currently available therapies are mostly based 
on those used to treat asthma. However, such compounds are not able to effectively reduce 
the gradual functional deterioration, as well as the ongoing airway and lung inﬂ  ammation 
occurring in COPD patients. Therefore, there is an urgent need to improve the efﬁ  cacy of the 
existing drug classes and to develop new treatments, targeting the main cellular and molecular 
mechanisms underlying disease pathogenesis. These therapeutic strategies will be highlighted 
in the present review.
Keywords: COPD, bronchodilators, anti-inflammatory drugs, cytokine and chemokine 
antagonists, signal transduction inhibitors 
Introduction
COPD is a chronic respiratory disease characterized by a progressive, not fully 
reversible airﬂ  ow limitation, which is associated with an abnormal inﬂ  ammatory 
response of the lungs to noxious particles or gases (Celli et al 2004). In particular, 
the main risk factor for COPD is tobacco smoking, whose pathogenic action may be 
potentiated by other harmful agents such as air pollution. However, because about 
20% of COPD patients are not smokers and only 15%–20% of smokers develop 
COPD, a genetically based individual susceptibility also plays an important role in 
disease pathogenesis. Indeed, in addition to the well known defects occurring in the 
α1-antitrypsin gene, which are responsible for a very small percentage of COPD cases, 
several different polymorphisms involving other genes encoding tumor necrosis factor-
α (TNF-α), matrix metalloproteinases (MMPs), antioxidants, and other molecules have 
also been detected (Molﬁ  no 2004). These complex interactions between environmental 
and genetic factors make COPD one of the leading causes of death worldwide, and 
the current epidemiological projections predict further increases in its prevalence and 
mortality during the next decades.
The main cellular elements of the inflammatory process that characterizes 
COPD include neutrophils, macrophages, and predominantly cytotoxic (Tc) CD8+ 
T lymphocytes (Lacoste et al 1993; Saetta et al 1999;  Shapiro 1999). Migration 
and activation of these cells are mediated by a complex network of cytokines and 
chemokines synthesized by both inﬂ  ammatory and resident cells, the latter including 
ﬁ  broblasts, and epithelial, endothelial, and airway smooth muscle cells. In COPD, 
airway and lung inﬂ  ammation is associated with pulmonary structural changes, arising 
from a relative imbalance between elastolytic proteinases and their inhibitors (Shapiro 
and Ingenito 2005). Therefore, the resulting altered turnover of extracellular matrix 
leads to the parenchymal destruction and loss of elastic recoil typical of emphysema. 
Conversely, collagen deposition and ﬁ  brosis characterize the small airways, thereby 
thickening their wall and further contributing to airﬂ  ow limitation in COPD. On 
the other hand, the same proteinases that cause elastolysis such as MMP-9, may 
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also activate ﬁ  brogenic growth factors like transforming 
growth factor-β (TGF-β), which is in turn involved in 
MMP-9 activation thus triggering a positive, feed-forward 
pathogenic circuit (Barnes et al 2003). Moreover, oxidative 
stress is heavily implicated in both the inﬂ  ammatory and 
tissue-damaging processes detectable in COPD patients, 
who are subjected to a remarkable oxidant burden due to 
cigarette smoking, air pollution, and intense metabolic 
activity of inﬂ  ammatory and structural cells (Maselli and 
Pelaia 2005).
Currently available therapies for COPD are mostly 
based on those used to treat asthma, mainly including 
bronchodilators and anti-inflammatory drugs such as 
corticosteroids. In COPD, however, these compounds are less 
effective than in asthma. With regard to bronchodilators such 
as long-acting β2-adrenergic agonists and anticholinergics, 
though airﬂ  ow limitation in COPD is characterized by poor 
reversibility, when given to COPD patients these drugs 
seem to be quite effective in improving lung function, 
exercise tolerance, and health status, as well as in reducing 
symptoms and frequency of exacerbations (Cazzola and 
Donner 2000; Casaburi et al 2002). Much more evident is 
the relatively low sensitivity of COPD patients to inhaled 
corticosteroids, possibly for several reasons including 
corticosteroid-dependent reduction of neutrophil apoptosis, 
putative resistance of CD8+ T cells to corticosteroids and, 
most importantly, oxidative stress-induced inhibition of 
expression and activity of histone deacetylases (HDACs) in 
alveolar macrophages (Ito et al 2005); HDACs are indeed 
essential for corticosteroid action in that these enzymes play 
a key role in remodeling chromatin structure and switching 
off pro-inﬂ  ammatory genes. 
Therefore, there is an urgent need to achieve a much 
better control of COPD, and ongoing pharmacological 
research is at least in part focused on improving the efﬁ  cacy 
of currently available drug classes, but it especially aims to 
develop novel therapeutic strategies, speciﬁ  cally targeting the 
main cellular and molecular mechanisms underlying disease 
pathogenesis. This review will outline the most promising 
approaches under development for COPD treatment, 
including improved bronchodilators and corticosteroids, as 
well as new compounds such as selective phosphodiesterase 
inhibitors, leukotriene modifiers, adhesion molecule 
blockers, tachykinin antagonists, inhibitors of cytokines 
and growth factors, chemokine inhibitors, anti-inﬂ  ammatory 
cytokines, inhibitors of transcription factors and intracellular 
signal transduction, proteinase inhibitors, and antioxidants 
(Table 1).
Improvements in existing classes 
of drugs
Improved long-acting β2-adrenoceptor 
agonists
Currently used long-acting β2-adrenoceptor agonists such 
as salmeterol and formoterol are, like all other marketed 
compounds of this drug class, racemic mixtures of both 
R(right)- and S(sinister)-isomers. However, only R-
enantiomers are pharmacologically active, whereas S-isomers 
are essentially inert (Handley et al 2000). Therefore, the 
newly developed pure R-form of formoterol (arformoterol) 
appears to be quite promising for a better control of COPD 
patients (Molﬁ  no 2005). Moreover, the pharmacological 
industry has tried to combine the therapeutic advantages 
of R-enantiomers with a once-daily dosing approach, thus 
developing a non-catechol, pure (R,R)-isomer and 24-hour-
lasting β2-agonist named carmoterol (TA-2005) (Kikkawa 
et al 1994; Cazzola et al 2005). This drug has been shown to 
have a high binding afﬁ  nity for β2-adrenergic receptors, and 
to be more potent than formoterol, salmeterol, salbutamol, 
procaterol, and isoprenaline. The carmoterol-derivative 
indacaterol (QAB-149) produces a very long bronchodilation, 
which lasts more than 24 hours, and preliminary clinical 
data suggest that such a compound is strongly efﬁ  cacious in 
COPD (Cazzola et al 2005). It can be thus argued that COPD 
patients will probably beneﬁ  t from these further advances in 
β2-agonist pharmacology. 
Improved anticholinergics
In addition to the long-acting tiotropium bromide, 
which dissociates slowly from M3 and M1 muscarinic 
receptors with respect to the inhibitory, pre-junctional M2 
autoreceptors, more selective M1/M3 antagonists are in 
clinical development. For instance, the M3 anti-muscarinic 
compound LAS34273 is a long-acting anticholinergic 
Table 1 New therapeutic interventions for COPD
Selective phosphodiesterase inhibitors
Leukotriene modiﬁ  ers
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characterized by a rapid and signiﬁ  cant bronchodilatory 
action, coupled with a good tolerability pattern in both 
healthy subjects and COPD patients (Schelfhout et al 2003). 
Revatropate is an M1/M3 antagonist, with no effect on M2 
autoreceptors and available for inhalation, which has been 
shown to be an effective and well-tolerated bronchodilator 
in COPD patients (Alabaster 1997). 
Improved corticosteroids
As already mentioned, corticosteroids are quite unable to 
suppress airway and lung inﬂ  ammation in COPD, mainly 
because of the inhibitory effect exerted by cigarette smoke 
and oxidative stress on histone deacetylation, which 
is required for the repressive action of corticosteroids 
on pro-inflammatory gene expression. However, the 
new, non-halogenated, inhaled glucocorticoid pro-drug 
ciclesonide is under development for both asthma and 
COPD (Dent 2002). This compound, which is converted 
into a ciclesonide-active principle (CIC-AP) in the lung, 
seems to be more potent than the currently available 
corticosteroid agents. 
Improved theophyllines
The current renewed interest for theophylline, whose 
clinical use has been quite neglected during recent years, 
arises from its suggested anti-inflammatory action, 
detectable even at low plasma concentrations (Barnes 2003). 
These newly recognized pharmacological properties are 
likely independent from either phosphodiesterase (PDE) 
inhibition or adenosine antagonism, and appear to be due 
to the ability of theophyllyne to activate HDACs (Barnes 
et al 2005). The latter mechanism may be very useful to 
restore HDAC activity impaired by oxidative stress, thus 
resensitizing COPD patients to the anti-inflammatory 
effects of corticosteroids. Therefore, there is a rational basis 
for a future design of novel theophylline-like molecules 
with improved HDAC-activating properties and devoid 
of the side-effects mainly caused by adenosine receptor 
antagonism. Such types of drugs could be indeed usefully 
utilized alone or in combination with corticosteroids, thereby 
increasing signiﬁ  cantly the therapeutic potential of these anti-
inﬂ  ammatory agents, rather limited in COPD at present. 
New therapeutic strategies
Selective phosphodiesterase inhibitors
At least 11 PDE families are currently known (Soderling 
and Beavo 2000), among which PDE4 is the predominant 
isoenzyme expressed in neutrophils, CD4+/CD8+ 
T cells, and monocytes/macrophages, as well as in airway 
epithelial and smooth muscle cells. Therefore, PDE4 
is a suitable therapeutic target for treatment of COPD 
(Sturton and Fitzgerald 2002). Speciﬁ  c PDE4 inhibitors 
such as cilomilast and roflumilast are active in some 
animal models of neutrophil inflammation and have 
been tested in COPD patients (Barnes and Hansel 2004). 
A 6-week study performed in patients with moderate 
to severe COPD showed that cilomilast improved lung 
function (Compton et al 2001), and this drug was also 
able to reduce airway inﬂ  ammation in biopsy samples 
(Gamble et al 2003). Furthermore, TNF-α release from 
peripheral blood monocytes was signiﬁ  cantly inhibited 
by roﬂ  umilast (Reid 2002), which in a placebo-controlled 
trial also increased FEV1 in COPD patients (Molfino 
2005). This latter compound is better tolerated than 
cilomilast, especially with regard to gastrointestinal side-
effects like vomiting, due to inhibition of the PDE4D 
gene preferentially expressed in the chemosensitive 
trigger zone in the brain stem (Lamontagne et al 2001). 
Cilomilast is indeed a selective PDE4D inhibitor 
whereas roﬂ  umilast does not target any speciﬁ  c member 
of the PDE4 family, thus exhibiting a more favorable 
therapeutic index that could be further improved by the 
future availability of selective inhibitors of the PDE4B 
isoform, which appears to play a prominent role in 
inﬂ  ammatory cells (Barnes and Stockley 2005).
Other PDE4 inhibitors in clinical development for 
COPD and asthma include ONO-6126, arofylline, and 
AWD-12-281. Oral administration of ONO-6126 has 
been reported to inhibit both airway inﬂ  ammation and 
bronchoconstriction (Molﬁ  no 2005). Inhaled arofylline, 
tested for 3 months in a double-blind, placebo-controlled 
Phase III trial involving 141 subjects with moderate to 
severe COPD, improved FEV1 and reduced the incidence 
of disease exacerbations (Molﬁ  no 2005). AWD-12-281 
is a new compound, already available as oral and inhaled 
formulations, which has the potential for inhibiting the 
release of pro-inﬂ  ammatory mediators such as histamine, 
TNF-α, and granulocyte-macrophage colony stimulating 
factor (GM-CSF), and appears to be effective also in in vivo 
models of airway diseases (Kuss et al 2003). More recently, 
a selective PDE7 inhibitor named BRL 50481 has been 
developed (Smith et al 2004) that targets the PDE7 isoform 
expressed by monocytes/macrophages, CD8+ T-cells, and 
neutrophils, thus potentiating the anti-inﬂ  ammatory actions 
of PDE4 inhibitors.International Journal of COPD 2006:1(3) 324
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Leukotriene modiﬁ  ers
Differently from the pathogenic mechanisms underlying 
asthma, which are characterized by an important role 
played by cysteinyl leukotrienes (LTC4, D4, E4), LTB4 is 
the leukotriene mostly involved in the inﬂ  ammatory process 
associated with COPD. In fact, LTB4 concentrations are 
markedly increased in both sputum and exhaled breath 
of patients with COPD (Hill et al 1999; Montuschi et al 
2003), especially during exacerbations. LTB4 interacts 
with the high-afﬁ  nity BLT1 receptor expressed by immune/
inﬂ  ammatory cells, thus exerting a powerful chemoattractant 
effect particularly on neutrophils, but also on CD8+ T-cells 
(Martin et al 1989; Goodarzi et al 2003).
Several selective BLT1 antagonists are currently under 
investigation for their potential therapeutic use in COPD. 
LY293111 and SB225002 are able to inhibit the neutrophil 
chemotactic activity of sputum from COPD patients 
(Crooks et al 2000; Beeh et al 2003). A powerful and long-
lasting activity characterizes the pharmacological proﬁ  le 
of the LTB4 receptor antagonist amelubant (BIIL-284), 
which is in clinical development for treatment of COPD, 
asthma, and cystic ﬁ  brosis (Birke et al 2001). BIIL-284 is 
an orally active pro-drug that is converted by ubiquitously 
expressed esterases into two active metabolites (BIIL-
260 and BIIL-315). A more limited therapeutic potential 
seems to characterize LTB 019, another LTB4 receptor 
antagonist that was tested in COPD patients, but did not 
elicit signiﬁ  cant changes in FEV1 as well as in induced 
sputum levels of neutrophils, TNF-α, and interleukin-8 
(IL-8) (Gronke and Beeh 2002). Since LTB4 is synthesized 
by 5′-lipoxygenase (5-LO), some 5-LO inhibitors such as 
CJ-13610 and BAYx1005 have been evaluated in COPD 
patients without showing marked activity in reducing 
sputum concentrations of LTB4 and neutrophil expression of 
activation markers (Gompertz and Stockley 2002). It is thus 
likely that more potent 5-LO inhibitors are still needed.
Adhesion molecule blockers
Airway and lung infiltration by inflammatory cells 
depends on their adhesion to vascular endothelium and the 
subsequent migration into the respiratory system. In this 
regard a key role is played by the expression on neutrophils, 
monocytes, CD8+ T-lymphocytes, and endothelial cells, 
of several different families of adhesion molecules, which 
represent another potential target for anti-COPD therapies 
(Matera and Cazzola 2004). For instance, rolling of 
inﬂ  ammatory cells along vascular endothelium is mediated 
by P-selectin, whose function may be inhibited by an 
antagonist (TBC1269) of its sialyl-LewisX ligand, which 
preferentially blocks neutrophil adhesion (Davenpeck et al 
2000). Another selectin inhibitor, the imidazole compound 
OC 229648, is under evaluation for treatment of COPD 
and asthma (Romano and Slee 2001). The Mac-1 (CD11b/
CD18) integrin might be a further interesting target because 
this adhesion molecule is overexpressed on neutrophils 
from COPD patients (Noguera et al 1998), and it is also 
present on the surface of monocytes and macrophages. 
However, these therapeutic approaches raise some concerns 
due to the possible risk of infections caused by a defective 
neutrophil migration.
Tachykinin antagonists
Antagonists of NK-1, NK-2, and NK-3 tachykinin receptors, 
stimulated by substance P (SP) and neurokinins A (NKA) 
and B (NKB), respectively, have been suggested to be 
potentially beneficial in both asthma and COPD (Joos 
and Pauwels 2001). Therefore, some single (NK-3), dual 
(NK-1/NK-2), or even triple (NK-1/NK-2/NK-3) orally 
active, NK receptor antagonists such as CS-003, DNK-333, 
and SB-223412 (talnetant), are in clinical development for 
COPD (Molﬁ  no 2005).
Inhibitors of cytokines and growth 
factors
TNF-α inhibitors 
TNF-α is a pro-inﬂ  ammatory cytokine involved in activation 
and migration of neutrophils, monocytes/macrophages, and 
T lymphocytes. In mice models, TNF-α is implicated in the 
pathogenesis of airway inﬂ  ammation sustained by neutrophils 
and macrophages, as well as in cigarette smoke-induced 
emphysema (Churg et al 2002). In COPD patients, high 
concentrations of this protein have been detected in induced 
sputum and plasma, and increased amounts of TNF-α-mRNA 
have also been found in skeletal muscles (Keatings et al 
1996; de Boer 2005). On the other hand, the severe wasting 
occurring in many patients with advanced COPD might be 
caused by TNF-α through the induction of skeletal muscle 
cell apoptosis. In support of this hypothesis, some TNF-α 
gene polymorphisms appear to be associated with a poorer 
disease prognosis (Keatings et al 2000).
Therefore, TNF-α seems to be a suitable target for the 
development of anti-COPD drugs, and different approaches 
have been tried to inhibit either the production or functions 
of this cytokine. Many of these compounds are in clinical 
trial for COPD and other chronic disorders such as asthma, International Journal of COPD 2006:1(3) 325
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Crohn’s disease, rheumatoid arthritis, and psoriasis. TNF-
α inhibitors include monoclonal, non-human or chimeric 
anti-TNF-α antibodies (infliximab, afelimomab, and 
CytoTab), humanized antibodies (adalimumab, CDP-571, 
CDP-870), human soluble TNF receptors (onercept) or 
TNF receptor fusion proteins (etanercept), and antisense 
oligonucleotides (ISIS-104838) that inhibit TNF-α mRNA 
translation into pre-TNF-α proteins (de Boer 2005). The 
aim of humanization is to reduce the immunogenicity of 
therapeutic antibodies and the consequent side-effects. 
The latter cannot, however, be completely avoided, in 
that local reactions around the site of injection and, less 
frequently, a delayed hypersensitivity-like reaction and a 
new onset of autoimmunity have also been reported (de 
Boer 2005). Very recently, the results of the ﬁ  rst Phase II 
clinical trial evaluating the effects of inﬂ  iximab in COPD 
patients have been published (van der Vaart et al 2005). 
According to this double-blind, placebo-controlled study 
involving 22 current smokers with mild to moderate COPD, 
14 of which received 3 infusions of inﬂ  iximab (5 mg/kg) 
at weeks 0, 2, and 6, respectively, such a treatment did 
not induce any change in respiratory symptoms, FEV1, 
quality of life, and percentage of inﬂ  ammatory cells in 
induced sputum. Anyway, larger and longer-term trials are 
still needed to better understand whether inﬂ  iximab may 
have a place in COPD management. Another anti-TNF-α 
strategy can be achieved by inhibiting TNF-α converting 
enzyme (TACE), which cleaves pre-TNF-α into the mature 
cytokine. Furthermore, TACE inhibitors (marimastat, 
BMS-561392, or DPC-33) may also reduce MMP activity 
and mucin 5AC production (Shao et al 2004), thereby 
providing potential additional beneﬁ  ts for COPD patients. 
However, anti-TNF-α therapies are only beginning to be 
evaluated for COPD treatment and, therefore, it is too 
early to predict the future impact of the above mentioned 
experimental approaches.
Interleukin-1 inhibitors 
Cigarette smoke and lipopolysaccharide (LPS) stimulate 
macrophages and epithelial cells to produce interleukin-
1 (IL-1), which in turn induces TNF-α expression in 
macrophages (de Boer 2005). When compared with healthy 
subjects, IL-1 concentrations have been reported to be 
increased in induced sputum from patients with mild COPD 
(Dignetti et al 2002). Anti-IL-1 strategies include the use of 
endogenous, soluble IL-1 receptor antagonists (sIL-1Ra), 
anti-IL-1 receptor antibodies, IL-1 binding proteins such as 
IL-1 Trap, anti-IL-1β antibodies (CDP 484), and inhibitors 
of IL-1β converting enzyme (ICE). A recombinant IL-1 
receptor antagonist (anakinra) has been already tested 
in subjects with rheumatoid arthritis, improving both 
symptoms and tissue damage typical of this chronic disease 
(Olsen and Stein 2004). Preliminary data suggest that 
administration of anakinra to patients with COPD may 
increase the risk of bacterial lung infections (de Boer 2005). 
However, despite the apparently disappointing results 
of these early clinical studies, the various approaches 
aimed at inhibiting IL-1 functions and/or synthesis might 
be potentially beneﬁ  cial in COPD, also because of the 
consequent reduction of TNF-α expression.
Interleukin-6 inhibitors 
In the exhaled breath condensate, as well as in serum during 
disease exacerbations, COPD patients exhibit elevated levels 
of interleukin-6 (IL-6) (Wedzicha et al 2000; Bucchioni et al 
2003), a pleiotropic cytokine released by several different 
cells and capable of stimulating the generation of cytotoxic 
T lymphocytes. Anti-IL-6 antibodies are currently in clinical 
development for many inﬂ  ammatory disorders (Nishimoto 
and Kishimoto 2004), and they should thus be experimented 
also for COPD treatment.
TGF-β inhibitors 
In patients with COPD, high expression levels of TGF-β 
are detectable in airway epithelium and macrophages of 
small airways (Takizawa et al 2001). TGF-β1 is a potent 
ﬁ  brogenic agent which plays a pivotal role in inducing 
the fibrosis and narrowing of peripheral airways that 
characterize obstructive bronchiolitis in COPD (Hogg et al 
2004). As already mentioned, TGF-β also contributes to 
proteinase imbalance by activating MMP-9. Furthermore, 
TGF-β has been shown to promote apoptosis of both 
bronchial and alveolar epithelial cells (Hagimoto et al 
2002; Pelaia et al 2003), which may represent a very initial 
event in COPD pathogenesis (Shapiro and Ingenito 2005). 
Therefore, the currently available low-molecular-weight 
inhibitors of TGF-β receptor kinase (Yakymovych et al 
2002) could be used to evaluate their effects in COPD 
patients.
Chemokine inhibitors
Among the four known families of chemokines, CC and 
CXC chemokines, synthesized by both inﬂ  ammatory and 
structural cells, are those mostly involved in regulating 
the traffic of macrophages, neutrophils, and CD8+ T International Journal of COPD 2006:1(3) 326
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lymphocytes, thus significantly contributing to COPD 
pathogenesis.
Inhibitors of monocyte/macrophage migration 
Migration of monocytes/macrophages is mainly mediated 
by CC chemokines including monocyte chemoattractant 
protein 1 (MCP-1 or CCL2), acting on its CCR2 receptor, 
and macrophage inﬂ  ammatory proteins 1α (MIP-1α or 
CCL3) and 1β (MIP-1β or CCL4), interacting with their 
CCR5 receptor. Both CCL2 and CCR2 proteins are highly 
expressed on macrophages from COPD patients (de Boer 
et al 2000; Traves et al 2002), thereby representing attractive 
targets for the development of small molecule antagonists 
(Figure 1). The humanized mouse monoclonal anti-CCL2 
antibody MLN1202 and the selective CCR2 antagonist 
INCB3284 have been taken into consideration for treatment 
of rheumatoid arthritis (de Boer 2005). Bindarit is another 
CCL2 antagonist that was shown to inhibit monocyte 
production of CCL2 and TNF-α, being also capable of 
reducing monocyte number in animal models of arthritis 
(Sironi et al 1999; Guglielmotti et al 2002). Binding of CCL2 
to its CCR2 receptor can also be blocked by RS-504393, 
which is able to inhibit macrophage infiltration and 
activation (Kitagawa et al 2004). Therefore, the potential 
utility of these compounds for COPD therapy should be 
explored.
With regard to the interactions between CCR5 receptor 
and its CCL3/CCL4 ligands, whose expression is increased in 
COPD, some CCR5 antagonists such as TAK220 and AK602 
are now available (Figure 1) (de Boer 2005). However, 
these drugs are unable to signiﬁ  cantly reduce macrophage 
chemoattraction because they inhibit only CCL3, but not 
CCL4 binding to CCR5, thus probably not being of particular 
interest for COPD treatment.
Inhibitors of neutrophil chemotaxis 
The CXC chemokines IL-8 (CXCL8) and growth-related 
oncoprotein-α (GRO-α or CXCL1) play a key role in 
neutrophil chemotaxis via stimulation of their CXCR1 
and CXCR2 receptors (Figure 2). IL-8 is overexpressed 
in COPD, thus being considered as an important target 
for therapeutic intervention (de Boer 2003; Fuke 2004). 
In a recent study, COPD patients received 3 injections 
(800 mg at baseline and 400 mg in the 2 subsequent 
months) of a monoclonal antibody (ABX-IL-8) against 
IL-8, which attenuated the severity of dyspnea without, 
however, improving lung function, quality of life, and 
performance of the 6-minute walking test (Mahler et al 
Figure 1 Main chemokine receptors expressed by macrophages. 
Macrophage
CCR5 CCR2
CCR2 ANTAGONISTS:
CCR5 ANTAGONISTS:
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2004). CXCL1- and IL-8-mediated neutrophil chemotaxis 
can be inhibited by the non-peptide CXCR2 antagonist 
SB33235, whose safety profile and pharmacokinetic 
characteristics are not yet known (de Boer 2005). 
SB656933 is another CXCR2 antagonist, currently under 
clinical investigation for COPD treatment, that was shown 
to impair neutrophil activation and recruitment into the 
bronchoalveolar lavage fluid (BALF) from rats exposed 
to aerosolized LPS (Carpenter et al 2004; Salmon et al 
2004).
Inhibitors of CD8+ T cell recruitment 
It has been recently suggested that COPD can be considered 
as an immunological disease featured by a predominant 
Tc1/Th1-mediated response (Di Stefano et al 2004). In 
fact, a signiﬁ  cant up-regulation of both interferon-inducible 
protein-10 (IP-10 or CXCL10) and its CXCR3 receptor, 
which is preferentially expressed by CD8+ Tc1 and CD4+ 
Th1 cells, was found in peripheral airways of COPD patients 
(Saetta et al 2002). Speciﬁ  c inhibitors of CXCL10/CXCR3 
interaction might therefore be useful for COPD treatment. 
In this regard, an anti-CXCL10 antibody has been recently 
developed and shown to inhibit CXCR3+ T cell recruitment 
in an experimental model of lung inﬂ  ammation (Hildebrandt 
et al 2004).
Anti-inﬂ  ammatory cytokines
In contrast to the pro-inﬂ  ammatory cytokines implicated in 
COPD pathophysiology, interleukin-10 (IL-10) may exert 
some anti-inﬂ  ammatory actions that could be exploited 
for therapeutic purposes. In particular, a recombinant 
human IL-10 (ilodecakin) is currently under evaluation for 
treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, 
and hepatitis C (Asadullah et al 2003). Administered to 
healthy volunteers before being exposed to endotoxin, IL-
10 reduced pulmonary neutrophilia and was also capable 
of inhibiting the expression of TNF-α, IL-6, IL-8, CCL2, 
CCL3, and CCL4 (Paikrt et al 1997). Repression of these 
pro-inﬂ  ammatory genes is probably due to the inhibitory 
effect of IL-10 on activation of the transcription factor 
nuclear factor-κB (NF-kB) (Driessler et al 2004). Clinical 
studies performed in patients with psoriasis showed that 
subcutaneous injections of IL-10 improved skin lesions and 
reduced the expression of Th1 cytokines (Asadullah et al 
2003), thus suggesting an IL-10-induced shift from Th1 
to Th2 immune response. This hypothesis appears to be 
Figure 2 Main chemokine receptors expressed by neutrophils. 
Neutrophil
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CXCR2 ANTAGONISTS
under clinical trial for COPD:
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conﬁ  rmed by trials involving patients with chronic hepatitis 
C infection, treated for up to 1 year with IL-10, who exhibited 
an improvement in liver histology associated with a shift from 
interferon (IFN)γ+CD8+ T cells towards a Th2 secretory 
pattern (Nelson et al 2003). However, subjects with either 
rheumatoid arthritis or Crohn’s disease did not experience 
signiﬁ  cant clinical improvements after treatment with IL-10, 
that surprisingly stimulated IFNγ expression and IFNγ-
dependent production of CXCL10 (Asadullah et al 2003), 
which may thus result in increased inﬂ  ammation associated 
with CXCR3+ T lymphocytes, as occurring in COPD. On 
the other hand, it has been recently reported that inhaled 
corticosteroid therapy may promote in COPD patients the 
production of IL-10 from alveolar macrophages, though this 
effect was not accompanied by signiﬁ  cant FEV1 increases 
(de Boer 2005). 
In vitro, in addition to decreasing the synthesis of TNF-α 
and IL-8 by macrophages, IL-10 also induced the expression 
of tissue inhibitor of metalloproteinase-1 (TIMP-1), without 
affecting MMP-9 levels (Lim et al 2000). Such actions might 
be particularly beneﬁ  cial for patients with COPD, who are 
characterized by an unbalanced proteinase/antiproteinase 
ratio, shifted towards lung tissue destruction. These patients 
also have, when compared with normal subjects, lower 
IL-10 concentrations in induced sputum (Takanashi et al 
1999). However, in order to better delineate the potential 
therapeutic use of IL-10, its pathogenetic role in COPD 
needs to be further elucidated. Moreover, recombinant IL-10 
can cause adverse side-effects including anemia, headache, 
and immunological reactions (de Boer 2005). Therefore, 
all these considerations at present preclude COPD patients 
from entering trials aimed at evaluating the clinical effects 
of IL-10.
Inhibitors of transcription factors
Among the transcription factors that regulate the expression 
of pro-inﬂ  ammatory cytokines and chemokines, a prominent 
role is played by NF-κB, which is activated in macrophages 
and epithelial cells of patients with COPD, especially during 
disease exacerbations (Di Stefano et al 2002; Caramori et al 
2003). NF-κB is a dimeric transcription factor which in its 
inactive form is bound in the cytoplasm to an inhibitory 
protein (inhibitor of NF-κB: IκB), that upon IκB kinase 
(IKK)-dependent phosphorylation undergoes ubiquitin-
mediated proteolysis thus resulting in the release of active 
NF-κB, able to translocate into the nucleus and to interact 
with the NF-κB binding sites of target genes (Baldwin 1996). 
Translation of NF-κB p65 subunit has been experimentally 
blocked in airway epithelial cells by small interfering 
(si)RNAs, which in vitro reduced the expression of both 
IL-6 and IL-8 (de Boer 2005). Furthermore, an antisense 
antagonist for p65 is now in clinical trial for Crohn’s disease 
(Hibi et al 2003).
A more promising approach is based on the use of orally 
active, small-molecule IKK inhibitors including SPC600839 
and BMS345541. In a mouse model of collagen-induced 
arthritis, BMS345541 was shown to suppress NF-κB nuclear 
translocation as well as TNF-α and IL-1β expression, thereby 
improving clinical symptoms and joint lesions (McIntyre 
et al 2003). Therefore, such compounds might be beneﬁ  cial 
in COPD by inhibiting the production of cytokines and 
chemokines by both inflammatory and structural cells. 
However, these therapeutic strategies should be considered 
with extreme caution in that a prolonged inhibition of NF-
κB, which is crucially involved in the control of innate and 
adaptive immune responses, could expose recipient patients 
to a high risk of infections.
Inhibitors of signal transduction 
pathways
Inhibitors of mitogen-activated protein kinases 
(MAPK) 
Among the various MAPK families (Figure 3), p38 is 
mostly implicated in cytokine biosynthesis as well as in 
recruitment of inﬂ  ammatory cells (Pelaia et al, 2005). 
In particular, p38 MAPK significantly contributes to 
neutrophil recruitment by up-regulating the vascular 
expression of intercellular adhesion molecule-1 (ICAM-1) 
and the release of TNF-α into airspaces (Tamura et al 1998; 
Nick et al 2000). Moreover, monocyte differentiation and 
chemotaxis are regulated by p38, which also stimulates 
the release of TNF-α and macrophage inflammatory 
protein-2 (MIP-2) from human macrophages (Ayala 
et al 2000; Nick et al 2000). Several pyridinylimidazole 
inhibitors of p38 are now available, and the combination of 
mutagenesis studies, X-ray crystallography and mechanistic 
enzymology has enabled elucidation of the molecular 
basis of inhibitor speciﬁ  city, as well as development of 
second-generation compounds with increased potency 
and selectivity (Wang et al 1998; Lee et al 2000; English 
and Cobb 2002). The ﬁ  rst p38 inhibitors able to block the 
biosynthesis of pro-inﬂ  ammatory cytokines included the 
bicyclic pyridinylimidazole SKF 86002 and the 2,4,5-triaryl 
imidazole SB 203580 (Lee et al 1993; Gallagher et al 1995). 
Subsequently, other compounds such as SB 220025, HEP International Journal of COPD 2006:1(3) 329
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689, and VX-745 have been designed; more recently, 
combinatorial chemistry strategies have led to the 
identiﬁ  cation of a new class of highly potent p38 inhibitors, 
characterized by the replacement of the pyrazole ring with 
either an isoxazole or a thiophene (Dumas et al 2000). These 
latter molecules are very promising, as shown by their ability 
to inhibit, within a submicromolar range of concentrations, 
IL-6 production induced by TNF-α and IL-1.
Over the past few years, the potential therapeutic 
role of p38 inhibitors has been tested in several different 
models of lung inflammation. SB 239063, a small- 
molecule p38 inhibitor, attenuated neutrophil inﬁ  ltration 
induced by inhaled LPS and decreased IL-6 and MMP-9 
levels in rat BALF (Underwood et al 2000), thus being 
possibly useful for COPD treatment. Another p38 
inhibitor, SD-282, reduced LPS-induced production of 
TNF-α by human lung macrophages, without affecting 
the expression of IL-8 (de Boer 2005). IL-8 release into 
cell-free supernatants of primary cultures of human 
bronchial epithelial cells, exposed to oxidative stress, was 
signiﬁ  cantly inhibited by SB 203580 (Pelaia et al 2004). 
In these same cell cultures, SB 203580 completely 
prevented apoptosis elicited by TGF-β (Pelaia et al 2003). 
On the basis of all such in vitro ﬁ  ndings, a p38 inhibitor 
named GSK-681323 has been developed for treatment 
of COPD, atherosclerosis, and rheumatoid arthritis, 
but clinical data are not yet available (Molﬁ  no 2005). 
However, the pharmacological strategy of inhibiting p38 
MAPK should be considered with caution as a treatment 
option in mammalian diseases, in that p38α knockout mice 
are characterized by a defective placental development 
(Adams et al 2000; Mudgett et al 2000). An alternative 
therapeutic approach might thus consist of targeting 
the p38 substrate mitogen-activated protein kinase-
activated protein kinase 2 (MAPKAP-K2) (Figure 3), 
which mediates the stabilizing function exerted by p38 
MAPK on many mRNAs encoding pro-inflammatory 
cytokines (Winzen et al 1999). This strategy, however, also 
raises some concern because MAPKAP-K2 is probably 
required for the optimal effectiveness of immune 
responses; indeed, mice carrying a mutation in the 
gene encoding MAPKAP-K2 are highly susceptible 
Figure 3 Mitogen-activated protein kinases (MAPK) signalling pathways.
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to infections by intracellular pathogens such as Listeria 
monocytogenes (Lehner et al 2002). A more suitable 
approach could thereby be represented by the development 
of inhalant formulations of either p38 or MAPKAP-K2. 
Inhibitors of phosphoinositide 3-kinase (PI-3K) 
The PI-3K enzymatic pathway, leading to the generation 
of lipid second messengers, provides pro-inﬂ  ammatory 
signals involved in recruitment and activation of neutrophils, 
monocytes, and T lymphocytes. Knockout of the PI-3Kγ is 
indeed responsible for inhibition of neutrophil migration 
and activation, as well as for impairment of T cell and 
macrophage functions (Sasaki et al 2000). Therefore, the 
selective  small-molecule  inhibitors  of  PI-3Kγ  which  are 
now in development may exert anti-inﬂ  ammatory actions 
potentially useful for COPD therapy (Ward et al 2003; 
Barnes and Stockley 2005).
Proteinase inhibitors
COPD is characterized by a relevant imbalance between 
proteinases (serine elastases, cysteine proteinases, MMPs), 
which degrade elastin and other structural proteins of lung 
parenchyma, and the protective array of antiproteinases 
(α1-antitrypsin, elafin, secretory leukoprotease inhibitor, 
and tissue inhibitors of MMPs) (Barnes et al 2003). In 
fact, smokers with a rapid decline in pulmonary function 
exhibit an increased urinary excretion of desmosine, a 
compound derived from elastin cross-links (Gottlieb et al 
1996), which is a marker of connective tissue destruction. 
Neutrophil elastase is a powerful proteolytic enzyme that 
is predominantly inhibited by α1-antitrypsin (α1-AT). 
The latter is currently administered as an extracted protein 
to patients with genetically determined, low serum levels 
of α1-AT and concomitant lung disease (Sandhaus 2004). 
In future, α1-AT could be provided in recombinant 
form or delivered by viral vector-driven gene strategies 
(Luisetti and Travis 1996; Stecenko and Brigham 2003). 
Furthermore, synthetic inhibitors of neutrophil elastase 
have been developed, including ONO-5046, FR901277, 
DX-890, and midesteine (Luisetti et al 1996; Fujie 
et al 1999; Barnes and Stockley 2005; Molfino 2005). 
In animal models, FR901277 neutralized the action of 
elastase and other neutrophil serine proteinases such 
as cathepsin and proteinase 3, thus inhibiting acute 
inflammation and pulmonary emphysema (Fujie et al 
1999). DX-890 is a recombinant protein derived from 
the human inter-α-trypsin inhibitor (Wark 2002), which 
after inhalation was well tolerated and detectable in 
its active form in BALF from healthy volunteers (Molﬁ  no 
2005). Midesteine is an orally active elastase inhibitor that, 
given for 4 weeks to patients with COPD, in a subgroup 
of treated subjects induced a post-treatment decrease of 
urine desmosine levels (Luisetti et al 1996). Non-selective 
MMP inhibitors such as marimastat seem to induce relevant 
muscular-skeletal side-effects (Belvisi and Bottomley 
2003). This problem could perhaps be overcome by the 
development of specific inhibitors of MMP-9 (Matter 
and Shudok 2004), which is the major elastolytic enzyme 
released by alveolar macrophages from COPD patients 
(Russell et al 2002).
Antioxidants
Oxidative stress plays a key role in the development of 
COPD, in that the major cause of this disease is cigarette 
smoking, which represents a rich source of oxidant 
agents. Furthermore, other factors involved in COPD 
pathogenesis and progression, such as air pollutants, 
occupational dusts, and respiratory infections, also have 
the ability to produce oxidative stress. Indeed, smokers 
and patients with COPD are characterized by high 
concentrations of exhaled hydrogen peroxide (H2O2), 
which become even higher during disease exacerbations 
(MacNee 2001). Moreover, increased levels of lipid 
peroxides, including 8-isoprostane and hydrocarbons such 
as ethane and pentane, are also detectable in the exhaled 
air condensate of patients with COPD (Habib et al 1995). 
Lipid peroxidation products positively correlate with 
airway obstruction, thus suggesting that oxidative stress 
is closely associated with the progressive decline in lung 
function occurring in COPD (Boots et al 2003). In addition, 
oxidative inactivation of the antiproteinase α1-AT favors 
the increase in elastase burden which is responsible for 
the development of pulmonary emphysema. Oxidants 
largely contribute to the inflammatory and structural 
changes underlying COPD by inducing the production 
of several mediators and cytokines such as TNF-α and 
IL-8. In this regard, we have reported that H2O2 elicited 
a concentration-dependent increase in the amount of IL-8 
released from bronchial epithelial cells, whose apoptotic 
death was also stimulated by oxidative stress (Pelaia et al 
2004). H2O2 is also able to induce, in a time-dependent 
manner, the acetylation of histone H4 and the closely 
related synthesis of IL-8 by both bronchial and alveolar 
epithelial cells (Gilmour et al 2003; Tomita et al 2003). 
In other cell types such as alveolar macrophages, it has 
been shown that H2O2 and cigarette smoke can stimulate International Journal of COPD 2006:1(3) 331
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IL-8 secretion by inhibiting the activity of HDAC enzymes 
(Ito et al 2001). HDACs indeed repress gene transcription 
by deacetylating core histones, thus enhancing chromatin 
condensation and DNA supercoiling (Ayer 1999). In 
particular, oxidative stress might impair HDAC activity 
by enhancing, in the presence of high NO levels, the 
production of peroxynitrite and the subsequent nitration 
of tyrosine residues on HDAC or associated proteins. This 
mechanism could also help explain the low therapeutic 
efficacy, observed in COPD patients when compared 
with asthmatics, of inhaled glucocorticoids, whose anti-
inflammatory actions largely depend on their ability to 
recruit and activate HDACs (Barnes et al 2004).
Therefore, antioxidants may exert potentially beneﬁ  cial 
effects in COPD. In fact, in rats exposed to tobacco smoke, 
the intra-tracheal administration of a catalytic antioxidant 
(AEOL 10150) elicited a significant decrease in BAL 
neutrophils and macrophages, detected at 2 days and 8 weeks, 
respectively (Crapo 2003). Anti-oxidant defences can be 
potentiated by the cysteine-donor N-acetyl cysteine (NAC), 
able to stimulate the production of the endogenous tripeptide 
glutathione (GSH), which provides an effective intra- and 
extracellular shield against oxidative stress. However, a 
large trial carried out on 523 patients with COPD, randomly 
receiving oral NAC (600 mg daily) or placebo for 3 years, 
has very recently demonstrated that NAC did not produce 
any change neither in the annual decline in FEV1 nor in the 
number of exacerbations per year (Decramer et al 2005). 
Nacystelyn is a NAC-related thiol antioxidant that has been 
shown to be effective in vitro, as well as in in vivo animal 
models (Antonicelli et al 2004); it also has the advantage of 
being suitable for aerosolized administration. Furthermore, 
the development of more powerful antioxidants including 
stable GSH compounds, analogs of superoxide dismutase, 
and selenium-based drugs is underway (Barnes and Stockley 
2005). In this regard, the potential therapeutic utility for 
COPD of BXT-51072, the lead compound in a series of 
small-molecule GSH peroxidase mimics, is interesting. 
BXT-51072 is capable of increasing the rate of peroxide 
metabolism, as well as of inhibiting both inﬂ  ammation and 
oxidative damage (Molﬁ  no 2005).
Conclusions
Because COPD is not currently well controlled by 
available drugs, which are unable to resolve inﬂ  ammation 
and to prevent lung tissue destruction and the associated 
progressive decline in pulmonary function, novel and more 
effective therapies are badly required. This need is made 
even more urgent by the known difﬁ  culties, due to both 
addiction and psychological reasons, encountered by 
patients and healthy subjects trying to quit smoking. 
Therefore, the common goal of the several different 
experimental approaches in development for COPD 
treatment should be a more successful targeting of disease 
causative mechanisms. In this regard, there is no doubt that 
during the past few years signiﬁ  cant progress has been made 
towards a better understanding of COPD pathophysiology. 
As a result, such new advances have led to a signiﬁ  cant 
expansion of the pharmacological options now under 
evaluation. Within this renewed therapeutic context, many 
strategies appear to be quite promising for the near future, 
including selective PDE inhibition, interferences with the 
cytokine/chemokine network, and blockade of MAPK 
signal transduction pathways. However, knowledge of 
the basic cellular and molecular events underlying COPD 
pathogenesis still needs to be further improved, possibly 
through the identiﬁ  cation of the genetic factors involved, 
and also via the application of proteomic techniques aimed 
at characterizing the speciﬁ  c patterns of protein expression 
related to the various COPD phenotypes. The potential 
future achievements will probably open the way for exciting 
perspectives, thus theoretically leading to the design of 
compounds capable of either directly modulating relevant 
genes or, alternatively, targeting their protein products.
Finally, a further contribution to the progress of COPD 
treatment may arise from the so-called regenerative medicine, 
aimed at restoring the integrity of lung tissue structure, 
destroyed in patients with emphysema. In particular, 
interesting data have been provided by experiments 
showing the activation of growth and repair processes in 
rat alveoli, induced by retinoic acid (Belloni et al 2000). In 
this regard, more beneﬁ  cial results may perhaps be pursued 
by biological strategies based on the use of stem cells (Otto 
2002). Therefore, our hope is that the combination of all 
these new approaches will eventually enable, in the next 
decades, a deﬁ  nitive cure for such a widespread and severe 
respiratory disease. 
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